4D Molecular Therapeutics, Inc.
FDMT
$4.11
-$0.17-3.97%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 105.26% | -99.99% | -97.91% | -90.60% | -101.52% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 105.26% | -99.99% | -97.91% | -90.60% | -101.52% |
| Cost of Revenue | 65.54% | 53.53% | 35.09% | 24.35% | 21.06% |
| Gross Profit | -65.42% | -691.46% | -36.45% | -25.90% | -28.61% |
| SG&A Expenses | 22.88% | 38.84% | 20.59% | 28.80% | 25.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 53.19% | 49.61% | 31.15% | 25.52% | 22.24% |
| Operating Income | -53.11% | -265.91% | -32.11% | -26.67% | -27.62% |
| Income Before Tax | -53.86% | -327.49% | -18.02% | -12.97% | -17.91% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -53.86% | -327.49% | -18.02% | -12.97% | -17.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -53.86% | -327.49% | -18.02% | -12.97% | -17.91% |
| EBIT | -53.11% | -265.91% | -32.11% | -26.67% | -27.62% |
| EBITDA | -54.77% | -284.76% | -32.86% | -27.12% | -28.31% |
| EPS Basic | -18.54% | -225.18% | 18.16% | 24.97% | 10.63% |
| Normalized Basic EPS | -18.53% | -225.12% | 18.14% | 24.97% | 10.63% |
| EPS Diluted | -18.54% | -225.18% | 18.16% | 24.97% | 10.63% |
| Normalized Diluted EPS | -18.53% | -225.12% | 18.14% | 24.97% | 10.63% |
| Average Basic Shares Outstanding | 29.80% | 31.47% | 44.21% | 50.57% | 31.94% |
| Average Diluted Shares Outstanding | 29.80% | 31.47% | 44.21% | 50.57% | 31.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
